NO20054072L - Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. - Google Patents

Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Info

Publication number
NO20054072L
NO20054072L NO20054072A NO20054072A NO20054072L NO 20054072 L NO20054072 L NO 20054072L NO 20054072 A NO20054072 A NO 20054072A NO 20054072 A NO20054072 A NO 20054072A NO 20054072 L NO20054072 L NO 20054072L
Authority
NO
Norway
Prior art keywords
antagonist
therapeutic agent
spinal cord
cord injury
interleukin
Prior art date
Application number
NO20054072A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054072D0 (no
Inventor
Hideyuki Okano
Seiji Okada
Masaya Nakamura
Kazuyuki Yoshizaki
Original Assignee
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio filed Critical Univ Keio
Publication of NO20054072D0 publication Critical patent/NO20054072D0/no
Publication of NO20054072L publication Critical patent/NO20054072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20054072A 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. NO20054072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003046214 2003-02-24
PCT/JP2004/002111 WO2004073741A1 (ja) 2003-02-24 2004-02-24 インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤

Publications (2)

Publication Number Publication Date
NO20054072D0 NO20054072D0 (no) 2005-09-01
NO20054072L true NO20054072L (no) 2005-10-25

Family

ID=32905544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054072A NO20054072L (no) 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Country Status (17)

Country Link
US (1) US20060165696A1 (pt)
EP (1) EP1607100A4 (pt)
JP (1) JP4555924B2 (pt)
KR (1) KR101142624B1 (pt)
CN (2) CN100340294C (pt)
AU (1) AU2004212843B2 (pt)
BR (1) BRPI0407747A (pt)
CA (1) CA2516945A1 (pt)
HK (1) HK1088230A1 (pt)
HR (1) HRP20050837A2 (pt)
IL (3) IL170399A (pt)
MX (1) MXPA05008713A (pt)
NO (1) NO20054072L (pt)
NZ (1) NZ541928A (pt)
PL (1) PL378199A1 (pt)
RU (2) RU2358761C2 (pt)
WO (1) WO2004073741A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324639A (ja) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2003211991B2 (en) * 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8398980B2 (en) * 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) * 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
WO2007086490A1 (ja) * 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
JP2009545319A (ja) * 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド 抗ｉｌ−６モノクローナル抗体およびその使用
BRPI0806812B8 (pt) * 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
MX2009012492A (es) 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Anticuerpos para il-6 y sus usos.
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
TWI609965B (zh) * 2007-05-21 2018-01-01 艾爾德生物控股有限責任公司 新穎兔抗體人化方法以及經人化之兔抗體
US7709215B2 (en) * 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
JP2013541594A (ja) 2010-11-08 2013-11-14 ジェネンテック， インコーポレイテッド 皮下投与される抗ｉｌ−６受容体抗体
EP2643016A2 (en) 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
WO2012118813A2 (en) * 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
KR20220064039A (ko) 2020-11-11 2022-05-18 정성삼 척수 손상 예방 또는 치료용 조성물
KR102320780B1 (ko) 2021-01-29 2021-11-02 정성삼 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
US6261560B1 (en) * 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
AU1122099A (en) * 1997-10-27 1999-05-17 Curis, Inc. Enhancement of morphogen activity
DE69934096T2 (de) * 1998-02-13 2007-07-05 The Wistar Institute Zusammensetzungen und methoden zur wundheilung
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders

Also Published As

Publication number Publication date
IL170399A (en) 2011-02-28
US20060165696A1 (en) 2006-07-27
IL200098A (en) 2012-10-31
NO20054072D0 (no) 2005-09-01
JPWO2004073741A1 (ja) 2007-08-23
HK1088230A1 (en) 2006-11-03
RU2358761C2 (ru) 2009-06-20
PL378199A1 (pl) 2006-03-06
CN1753694A (zh) 2006-03-29
EP1607100A1 (en) 2005-12-21
JP4555924B2 (ja) 2010-10-06
KR101142624B1 (ko) 2012-06-15
CN100340294C (zh) 2007-10-03
MXPA05008713A (es) 2005-09-20
AU2004212843B2 (en) 2009-06-25
EP1607100A4 (en) 2007-06-13
CN101130077A (zh) 2008-02-27
BRPI0407747A (pt) 2006-02-14
KR20060006004A (ko) 2006-01-18
WO2004073741A8 (ja) 2005-04-07
WO2004073741A1 (ja) 2004-09-02
NZ541928A (en) 2009-06-26
IL205618A (en) 2012-02-29
RU2005130011A (ru) 2006-02-10
AU2004212843A1 (en) 2004-09-02
RU2009102845A (ru) 2010-08-10
HRP20050837A2 (en) 2005-12-31
CA2516945A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
NO20054072L (no) Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
DK1478399T3 (da) Oral dosisform indeholdende en pde-4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidone som excipiens
DK1364946T3 (da) Isoxazolin-derivat og herbicid omfattende samme som aktiv bestanddel
NO20064127L (no) Terapeutisk middel for Auris interna forstyrrelse, inneholdende IL-6 antagonist som aktiv bestanddel
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20054681L (no) Farmasoytiske produkter
WO2006087206A3 (en) Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (lsd1)
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO20062150L (no) Nye ketooksadiazolderivater som katepsinhibitorer
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
NO20070431L (no) Kjemiske forbindelser I
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
AR053154A1 (es) Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application